证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 编号：2025-11 | 投资者关 | □特定对象调研 □分析师会议 | | --- | --- | | 系活动类 | □媒体采访 □业绩说明会 | | 别 | □新闻发布会 路演活动 ☑ | | | □现场参观 | | | 其他（华安证券策略会） | | 参与单位 | 天弘基金 钟颖 李佳豪、工银瑞信基金 李乾宁、民生加银基金 尹 | | 名称及人 涛 | 郝梦娇； | | 员姓名 | 参加华安证券策略会，面向华安证券邀请的投资者，包括 Nature | | | Capital 苗天一、禾晟投资 章孝林、海衍投资 丁威、山西证券 杨 | | | 杰、上海润义投资 陆懿晨、信迹投资 宋文略、绅徽投资 陈彦宁等。 | | 时间 2025 | 年 12 月 18 日 | | 地点 | 路演：天弘基金、工银瑞信基金、民生加银基金公司会议室 | | | 华安证券策略会：陆家嘴富汇大厦 A 座 | | 上市公司 | 董事会秘书 刘泽霖 | | 接待人员 | 投资者关系总监 董丁梦 | | 姓名 | | | | 1、请介绍下公司 ...

Group 1 - The high-pressure oxygen chamber concept increased by 2.20%, ranking fourth among concept sectors, with eight stocks rising, including Jinling Pharmaceutical, BeiYikang, and Innovation Medical, which rose by 6.35%, 5.73%, and 3.79% respectively [1] - The main capital inflow for the high-pressure oxygen chamber concept was 0.29 billion yuan, with five stocks receiving net inflows, led by Innovation Medical with a net inflow of 52.09 million yuan [2][3] - The net inflow ratios for International Medical, Innovation Medical, and Jinling Pharmaceutical were 9.48%, 5.21%, and 3.12% respectively, indicating strong investor interest in these stocks [3] Group 2 - The top gainers in the high-pressure oxygen chamber concept included Innovation Medical, International Medical, and Jinling Pharmaceutical, while the top losers were Samsung Medical and Hangyang Co., which fell by 3.20% and 1.14% respectively [1][4] - The trading volume for Innovation Medical was 11.31%, indicating a high turnover rate, while other stocks like International Medical and Jinling Pharmaceutical had lower turnover rates of 1.77% and 4.54% respectively [3]

证券代码：300143 证券简称：盈康生命 公告编号：2025-048 盈康生命科技股份有限公司 关于 2023 年限制性股票激励计划首次授予部分第二个归属期、 预留授予部分第一个归属期归属结果暨股份上市公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次归属限制性股票的上市流通日：2025 年 12 月 15 日； 2、本次归属股票数量：1,638,957 股，占归属前上市公司总股本的 0.22%， 其中首次授予部分第二个归属期限制性股票归属数量 1,259,945 股，预留授予部 分第一个归属期归属数量 379,012 股； 3、本次归属人数：173 人，其中首次授予部分第二个归属期归属的激励对 象 153 人，预留授予部分第一个归属期归属的激励对象 20 人； 4、本次归属股票价格：5.08 元/股； 5、本次归属股票来源：公司在二级市场回购的本公司 A 股普通股股票； 2023 年 9 月 12 日，公司召开 2023 年第三次临时股东大会，审议并通过了 1 《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》 ...

（文章来源：证券日报） 证券日报网讯 12月12日，盈康生命在互动平台回答投资者提问时表示，截至2025年12月10日，公司股 东总数为20115户。 ...

Core Insights - The China Securities Association released the results of the "2025 Evaluation of Board Secretaries of Listed Companies," with 282 board secretaries receiving a 5A rating, 589 receiving a 4A rating, and 687 receiving a 3A rating [1] - The evaluation criteria included ten major standards and 67 indicators, covering areas such as compliance, information disclosure, internal control, investor relations management, and social responsibility [1] - Board secretaries play a crucial role in corporate governance, acting as gatekeepers for compliance and as a bridge between the capital market, investors, and company management [1] Group 1 - A total of 282 board secretaries achieved the highest 5A rating, reflecting their exceptional performance and the governance standards of their respective companies [1] - The evaluation emphasizes the importance of board secretaries in maintaining corporate transparency and sustainable development [1] - The recognition of board secretaries is not only a personal accolade but also highlights the benchmark status of their companies in governance and transparency [1] Group 2 - Notable companies with 5A rated board secretaries include COSCO Shipping Energy, Fosun Pharma, and Kweichow Moutai, among others [2] - The list of 5A rated board secretaries includes individuals such as Ni Yidan from COSCO Shipping Energy and Dong Xiaoxian from Fosun Pharma [2] - The evaluation results serve as a reference for best practices in corporate governance and investor relations within the industry [1][2]

（编辑 王雪儿） 证券日报网讯 12月5日，盈康生命在互动平台回答投资者提问时表示，公司始终高度重视市值管理，并 坚持在聚焦主业、提升经营效率和盈利能力的基础上，综合运用包括增持回购、股权激励、非公开发行 股票、并购等方式系统性地强化市值管理与投资者回报。2025年，公司审议通过了旨在完善治理与回报 机制的相关制度。外延发展方面，公司于2025年上半年完成对长沙珂信肿瘤医院51%股权的收购，旨在 进一步夯实在医疗服务领域的肿瘤特色，增厚业绩并增强持续经营能力。此外，公司始终致力于提升规 范运作与信息披露质量，以有效传递公司价值。 ...

Group 1 - The high-pressure oxygen chamber concept increased by 0.92%, ranking second among concept sectors, with eight stocks rising, including Hangzhou Oxygen, Dahu Co., and Jinling Pharmaceutical, which rose by 5.56%, 1.13%, and 1.09% respectively [1] - The leading stocks in terms of net inflow of main funds in the high-pressure oxygen chamber sector include Samsung Medical, with a net inflow of 4.9759 million yuan, followed by Aoyang Health, Yingkang Life, and Weiao Co. [2][3] - The net inflow ratios for Yingkang Life, Weiao Co., and Aoyang Health were 2.53%, 1.60%, and 1.49% respectively, indicating strong interest from main funds [3] Group 2 - The high-pressure oxygen chamber sector experienced a net outflow of 45 million yuan today, despite some stocks seeing net inflows [2] - Stocks with significant declines include Beiyikang, China Railway Construction, and Yingkang Life, which fell by 0.40%, 0.20%, and 0.20% respectively [1] - The trading volume and turnover rates for stocks like Hangzhou Oxygen and International Medical showed negative net inflows, indicating potential selling pressure [4]

Core Viewpoint - Yingkang Life is actively advancing the second phase of construction for Changsha Kexin Tumor Hospital, aiming to enhance its medical service capacity significantly [1] Group 1: Hospital Development - The hospital is expected to add over 400 new beds as part of its expansion efforts [1] - Major medical equipment updates and campus renovations have been completed, optimizing bed resources [1] - The goal is to establish the hospital as a leading tumor specialty hospital in Central China [1]

Group 1: Hospital Overview - Changsha Kexin Tumor Hospital officially opened in September 2015, approved by the Hunan Health Commission, and is a tertiary specialized cancer hospital [1][2] - The hospital occupies an area of 27 acres with an initial capacity of 420 beds, currently operating at full capacity, and employs over 500 staff [2] - It has been recognized with multiple awards, including "Excellent Department in Improving Medical Services" and "Top 100 Service Enterprises in Xiangjiang New Area" [2] Group 2: Differentiation and Service Model - The hospital focuses on a patient-centered service system, implementing a "Ten Fears and Ten Promises" service commitment mechanism to enhance patient experience [3] - The "Medical Square" service model integrates various professional resources to provide comprehensive, one-stop services, contributing to a sustainable brand reputation [3] Group 3: Technological and Equipment Advantages - In the first nine months of 2025, the hospital performed over 7,000 minimally invasive surgeries, with an 8% year-on-year increase [4] - The introduction of advanced DSA equipment increased monthly surgical volume from 465.5 to 788.4, a growth rate of 69% [5] - New radiation therapy equipment, such as TOMO-C, is expected to enhance precision treatment capabilities [5] Group 4: Future Development Plans - The hospital is preparing for a second phase of construction, aiming to add over 400 beds to expand medical service capacity [6] - The goal is to establish Changsha Kexin as a leading tumor specialized hospital in Central China, enhancing service capabilities and brand position [6] Group 5: Long-term Strategic Planning - The company embraces healthcare reform, aiming to provide timely detection, precise treatment, and rapid recovery through differentiated medical solutions [7] - The resource allocation strategy follows a "3/3/3" model, focusing on social healthcare, personalized services, and continuous health management for outpatients [8] - The company is transitioning from a traditional medical group to a health management technology company, leveraging AI to improve service efficiency and quality [8]

证券日报网讯12月1日，盈康生命（300143）在互动平台回答投资者提问时表示，截至2025年11月28 日，公司股东总数为20，122户。 ...